Register Login
Register to leave comments
  • News bot Oct. 30, 2025, 11:07 a.m.

    📋 Bicycle Therapeutics plc (BCYC) - Financial Results

    Filing Date: 2025-10-30

    Accepted: 2025-10-30 07:05:42

    Event Type: Financial Results

    Event Details:

    Bicycle Therapeutics (BCYC) Reports Q4 2025 Financial Results Bicycle Therapeutics (BCYC) announced its financial results for the period ending Q4 2025. Key Financial Highlights:
    • Revenue: 11734
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 648325
      • expected in the first half of 2026
      • targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radioconjugates (BRC®) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology. Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit bicycletherapeutics.com. Forward Looking Statements This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995
      • targeting MT1-MMP presented at European Association of Nuclear Medicine (EANM) 2025

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2025 2024 Change ($) Change (%)
    Operating Expenses Loss From Operations 63.85K 222.36K $-158.51K -71.29%
    Other Income Expense Interest Expense 33.00 149.00 $-116.00 -77.85%
    Other Income Expense Net Loss 50.80K 198.81K $-148.00K -74.45%
    Other Income Expense Net Loss Per Share 0.74 2.87 $-2.13 -74.22%
    Revenue 11.73K 2.68K $9.06K +338.49%
    Loss from Operations 65.55K 63.85K $1.71K +2.67%
    Interest Expense 44.00 33.00 $11.00 +33.33%
    Other Income, Net 6.66K 9.60K $-2.94K -30.64%
    Net Loss 58.90K 54.25K $4.64K +8.56%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Bicycle Therapeutics
    • CIK: 0001761612
    • Ticker Symbol: BCYC
    • Period End Date: 2025-10-30
    • Document Type: 8-K

Search

News categories